GB stock · Healthcare sector · Drug Manufacturers—General
Company Logo

GlaxoSmithKline plc

GSKNYSE

44.52

USD
+0.96
(+2.20%)
Market Closed
17.88P/E
13Forward P/E
0.69P/E to S&P500
113.169BMarket CAP
1.72%Div Yield

GlaxoSmithKline plc

NYSE:GSK

RECENT
PRICE

44.52

P/E
RATIO

17.88

(PEG:-0.74)

P/E RATIO
RELATIVE
TO S&P

0.69

DIV
YLD

3.79%

High:
Low:

0
0

0
0

0
0

0
0

0
0

0
0

0
0

0
0

0
0

0
0

0
0

0
0

0
0

0
0

0
0

0
0

Legends

Stock price

- - Beta (1.0 Market)

0

0

0

0

0

0

0

0

0

-

% total return 05/22:

Stock

S&P

1y.

0

0

3y.

0

0

5y.

0

0

0

Percent shares traded:

0

0

0

2006

2007

2008

2009

2010

2011

2012

2013

2014

2015

2016

2017

2018

2019

2020

2021

TTM

Fiscal year

8.23

1.91

0.98

0.92

8.23

1.89

1.46

1.01

9.31

1.80

1.96

1.15

11.19

2.18

2.35

1.22

11.16

0.64

2.03

1.26

10.89

2.09

1.96

1.35

10.76

1.86

1.16

1.55

10.97

2.25

2.29

1.52

9.57

1.15

1.42

1.60

9.90

3.49

0.28

1.60

11.48

0.38

1.71

2.00

12.36

0.63

1.93

1.60

12.54

1.47

2.70

1.60

13.65

1.88

2.37

1.60

13.71

2.31

2.49

1.60

13.64

1.75

2.01

1.60

14.56

2.04

2.79

1.60

Revenue per share

Earnings per share

Free Cash Flow per sh

Dividends per share

0.56

3.33

0.78

3.48

0.79

3.03

0.74

3.95

0.64

3.49

0.53

3.19

0.62

2.37

0.70

2.90

0.73

1.77

0.79

2.12

0.97

0.46

0.90

(0.03)

0.73

1.77

0.87

4.61

0.90

5.86

1.17

6.02

1.27

6.19

CAPEX per share

Book Value per share

2,822

2,762

2,616

2,535

2,545

2,514

2,456

2,416

2,404

2,416

2,430

2,443

2,457

2,474

2,488

2,502

2,505

Comm.Shares outs.(m)

28.2

1.6

1.7%

28.3

1.6

1.9%

23.9

1.1

2.7%

16.6

0.2

3.4%

59.3

2.9

3.3%

19.8

1.2

3.3%

24.3

1.6

3.4%

22.1

1.3

3.1%

43.9

2.4

3.2%

12.4

0.6

3.7%

110.1

5.0

4.8%

63.8

2.7

4.0%

26.7

1.1

4.1%

22.1

0.9

3.9%

17.3

0.5

4.0%

22.4

0.7

4.1%

17.9

0.7

3.8%

Avg. annual P/E ratio

P/E relative to S&P500

Avg. annual div. yield

Capital Structure (31/3/22 | Q1)

Total liabilities
$67,057 m.

Total assets
$89,689 m.

Long-term debt
$29,226 m.

Cash and equiv.
$10,967 m.

Goodwill $10,705 m.

Retained earnings $9,637 m.

Common stock 2,510 m. shares

Market Capitalisation
$114,836 m. (as of 21/5/22)

27,387

28.5%

26,431

28.0%

26,505

26.5%

23,006

15.6%

23,923

43.1%

27,889

9.3%

30,186

13.5%

30,821

17.8%

33,754

20.6%

34,099

22.8%

34,114

18.2%

36,476

20.0%

Revenue (m)

Operating margin

1,423

5,261

1,445

4,565

1,414

5,436

1,484

2,756

1,630

8,422

1,774

912

1,922

1,532

1,856

3,623

2,334

4,645

2,351

5,749

2,524

4,385

2,867

5,114

Depreciation (m)

Net profit (m)

29.1%

19.2%

29.1%

17.3%

15.3%

20.5%

4.6%

12.0%

20.5%

35.2%

45.2%

3.3%

38.5%

5.1%

15.7%

11.8%

15.3%

13.8%

8.3%

16.9%

6.4%

12.9%

0.5%

14.1%

Income tax rate

Net profit margin

1,157

12,203

8,032

(123)

14,671

5,810

1,550

15,456

6,997

1,383

15,841

4,263

3,170

15,324

5,114

(2,290)

14,661

1,124

(10,662)

14,264

(68)

(5,564)

20,271

4,360

(4,559)

23,590

11,405

(1,901)

23,425

14,587

(4,996)

20,572

15,055

4,710

29,226

16,181

Working capital (m)

Long-term debt (m)

Equity (m)

23.3%

20.6%

65.5%

19.3%

17.9%

78.6%

22.1%

17.4%

77.7%

12.9%

9.0%

64.6%

24.8%

22.8%

164.7%

3.8%

4.5%

81.1%

8.5%

6.9%

(2,252.9)%

12.0%

8.8%

83.1%

11.3%

8.9%

40.7%

12.7%

9.7%

39.4%

10.5%

7.6%

29.1%

10.8%

7.7%

31.6%

ROIC

Return on capital

Return on equity

Working Capital

2019

2020

2021

Cash assets

4,786

6,171

4,353

Receivables

- -

- -

- -

Inventory

5,947

5,996

5,783

Other

8,758

8,081

8,556

Current assets

19,491

20,247

18,674

Acc. Payable

4,144

4,357

17,554

Debt due

6,918

3,725

3,601

Other

12,988

14,066

2,515

Current liab.

24,050

22,148

23,670

35.3%

108.5%

16.5%

207.7%

32.3%

84.1%

(39.4)%

117.1%

54.0%

583.8%

(431.8)%

116.6%

(155.0)%

83.0%

(8.4)%

58.2%

14.9%

66.6%

30.8%

63.7%

8.8%

79.2%

26.9%

57.1%

Plowback ratio

Div.&Repurch. to FCF

GlaxoSmithKline plc (GB) started trading on September 2, 2001 (cik: 0001131399), operates in the Healthcare sector (Drug Manufacturers—General industry), has 90,096 full-time employees, and is led by Ms. Emma N. Walmsley. GlaxoSmithKline plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, HIV, immuno-inflammation, oncology, anti-viral, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterial, and dermatology. It also provides consumer healthcare products in wellness, oral health, nutrition, and skin health categories. The company offers its consumer healthcare products in the form of nasal sprays, tablets, syrups, lozenges, gum and trans-dermal patches, caplets, infant syrup drops, liquid filled suspension, wipes, gels, effervescents, toothpastes, toothbrushes, mouthwashes, denture adhesives and cleansers, topical creams and non-medicated patches, lip balm, gummies, and soft chews. It has collaboration agreements with 23andMe; Lyell Immunopharma, Inc.; Novartis; Sanofi SA; Surface Oncology; Progentec Diagnostics, Inc.; Alector, Inc.; and CureVac AG., as well as strategic partnership with IDEAYA Biosciences, Inc. and Vir Biotechnology, Inc. GlaxoSmithKline plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.

Annual rates

(avg rate of change)

Past
5 y.

Past
10 y.

Revenues

3.17%

3.17%

Cash flow

3.93%

58.33%

Earnings

41.18%

35.44%

Dividends

0.59%

1.09%

Book value

-1579.77%

-722.43%

Insider trading

Type

Shares

Date

Nothing found

Fiscal Year Ends

Quarterly Revenue (m)

Full fiscal year

I

II

III

IV

2020

9,090

7,624

8,646

8,739

34,099

2021

7,418

8,092

9,077

9,527

34,114

2022

9,780

- -

- -

- -

- -

Fiscal Year Ends

Earnings per share

Full fiscal year

I

II

III

IV

2020

0.63

0.91

0.50

0.27

2.31

2021

0.43

0.56

0.47

0.30

1.75

2022

0.72

- -

- -

- -

- -

Fiscal Year Ends

Quarterly dividends paid

Full fiscal year

I

II

III

IV

2020

0.38

0.46

0.38

0.38

1.60

2021

0.38

0.46

0.38

0.38

1.60

2022

0.38

- -

- -

- -

- -

01/19/2022

Unilever Walks Away From Glaxo Consumer-Healthcare Deal

The Wall Street Journal - Read more...

01/15/2022

Unilever Makes Approach for Glaxo’s Consumer-Healthcare Business

The Wall Street Journal - Read more...

12/07/2021

Tesla, Intel, Bitcoin: What to Watch in the Stock Market Today

The Wall Street Journal - Read more...

12/02/2021

Vir Biotechnology, Digital World Acquisition, Apple: What to Watch in the Stock Market Today

The Wall Street Journal - Read more...

05/17/2021

Sanofi-GSK Covid-19 Vaccine Set for Large-Scale Trials After Positive Results

The Wall Street Journal - Read more...